AAPS PharmSciTech最新文献

筛选
英文 中文
A New and Safe Delivery of Sildenafil Citrate Co-Evaporate Loaded Emulgels for the Cure of Certain Male Sexual Dysfunctions 一种新的、安全的递送柠檬酸西地那非共蒸发乳剂治疗某些男性性功能障碍
IF 3.4 4区 医学
AAPS PharmSciTech Pub Date : 2025-01-16 DOI: 10.1208/s12249-024-03027-x
Shaaban K. Osman, Abobakr M. Yassin, Taher M. Yassin, Ahmed M. Mohammed, Ahmed M. Abdelsalam, Wael A. Mahdi, Sultan Alshehri, Mohamed A. El Hamd, Ahmed A. H. Abdellatif, Mohammed A. Amin, Emad A. Taha
{"title":"A New and Safe Delivery of Sildenafil Citrate Co-Evaporate Loaded Emulgels for the Cure of Certain Male Sexual Dysfunctions","authors":"Shaaban K. Osman,&nbsp;Abobakr M. Yassin,&nbsp;Taher M. Yassin,&nbsp;Ahmed M. Mohammed,&nbsp;Ahmed M. Abdelsalam,&nbsp;Wael A. Mahdi,&nbsp;Sultan Alshehri,&nbsp;Mohamed A. El Hamd,&nbsp;Ahmed A. H. Abdellatif,&nbsp;Mohammed A. Amin,&nbsp;Emad A. Taha","doi":"10.1208/s12249-024-03027-x","DOIUrl":"10.1208/s12249-024-03027-x","url":null,"abstract":"<div><p>The present work focuses on the production of sildenafil co-evaporates loaded emulgels as topical dosage forms for the treatment of premature ejaculation and erectile dysfunction. Topical administration of sildenafil citrate (SILD) co-evaporates is expected to improve the bioavailability profile of the drug and to avoid the severe side effects accompanying the traditional SILD dosage forms, especially for prohibited cardiovascular cases. Firstly, the solubility of SILD was improved via solid dispersion via co-evaporation technique using PEG-5KDa and PVP-K90 as hydrophilic carriers. The modified co-evaporates were characterized by DSC, XRD, and solubility studies. Different emulgels, loaded with SILD co-evaporates, were formulated and characterized by different analyses including the viscosity, stability, spreadability, and <i>in vitro</i> release studies. Finally, the clinical activity of the chosen formula was accomplished via the application of the emulgels on volunteers suffering from erectile dysfunction. The results showed that the prepared SILD/PVP K90 of 1:2 w/w ratio exhibited the highest solubility and dissolution rate. All formulated emulgels exhibited good physicochemical properties. Especially, the emulgel formula composed of 2%w/v HPMC, loaded with SILD /PVP- K90, revealed the highest release rate. The release mechanism of SILD from emulgels fits with the Korsmeyer Peppas mechanism. The results of <i>in vivo</i> studies indicated a significant improvement of both IVLT and IIEF-5 parameters in mild to moderate ED, accompanied by PE. The modified SILD emulgel is an alternative promising and safe transdermal drug delivery system for the management and treatment of mild to moderate ED with PE.</p><h3>Graphical Abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":6925,"journal":{"name":"AAPS PharmSciTech","volume":"26 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142994492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Novel Facile and Efficient Prophylaxis Avenue of Chitosan Oligosaccharide/PLGA Based Polydatin Loaded Nanoparticles Against Bleomycin-Induced Lung Inflammation in Experimental Rat Model 低聚壳聚糖/PLGA负载多聚糖纳米颗粒对博莱霉素诱导大鼠肺炎症的一种新的简便有效的预防途径
IF 3.4 4区 医学
AAPS PharmSciTech Pub Date : 2025-01-16 DOI: 10.1208/s12249-024-03022-2
Ahmed Nashaat Alnagar, Amira Motawea, Randa A. Zaghloul, Mamdouh Eldesoqui, Irhan Ibrahim Abu Hashim
{"title":"A Novel Facile and Efficient Prophylaxis Avenue of Chitosan Oligosaccharide/PLGA Based Polydatin Loaded Nanoparticles Against Bleomycin-Induced Lung Inflammation in Experimental Rat Model","authors":"Ahmed Nashaat Alnagar,&nbsp;Amira Motawea,&nbsp;Randa A. Zaghloul,&nbsp;Mamdouh Eldesoqui,&nbsp;Irhan Ibrahim Abu Hashim","doi":"10.1208/s12249-024-03022-2","DOIUrl":"10.1208/s12249-024-03022-2","url":null,"abstract":"<div><p>Lung inflammation is a hallmark of several respiratory diseases. Despite the great effectiveness of the synthetic antiinflammatory agents, they cause potential side effects. Polydatin (PD), a natural phytomedicine, has antioxidant and antiinflammatory effects. Its clinical applications are hindered due to poor aqueous solubility, low bioavailability, and rapid metabolism by first-pass effect. Herein, we report the development of a novel chitosan oligosaccharide-coated PD-loaded Poly dl-lactide-co-glycolide nanoparticles (COS-coated PD/PLGA NPs) against a bleomycin-induced pulmonary inflammation in a rat model. The NPs exhibited a small particle size of 188.57 ± 5.68 nm and a high zeta potential of + 18.13 ± 2.75 mV with spherical architecture and sustained release pattern of PD. <i>In vivo</i> studies in bleomycin-induced lung inflammation in a rat model revealed the superior prophylactic activity of COS-coated PD/PLGA NPs over the free drug (PD) as demonstrated by histopathological and immunohistochemical analyses, alongside biochemical assays evaluating oxidative stress biomarkers and inflammatory cytokine levels. Overall, the optimized COS-coated PD/PLGA NPs formulation offers a promising prophylactic platform against many respiratory diseases.</p><h3>Graphical Abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":6925,"journal":{"name":"AAPS PharmSciTech","volume":"26 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1208/s12249-024-03022-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142994428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pediatric Formulation Optimization Using a Rational Design: Exploring Amorphous Solid Dispersion Technology with Terbinafine Hydrochloride as a Case Study 合理设计优化儿科配方:以盐酸特比萘芬为例探索非晶态固体分散技术
IF 3.4 4区 医学
AAPS PharmSciTech Pub Date : 2025-01-16 DOI: 10.1208/s12249-024-03012-4
Izabelle Amorim Ferreira Boza, Stéfani Laise da Silva, Nicolly Bittencourt Guedes, Giovana Carolina Bazzo, Hellen Karine Stulzer
{"title":"Pediatric Formulation Optimization Using a Rational Design: Exploring Amorphous Solid Dispersion Technology with Terbinafine Hydrochloride as a Case Study","authors":"Izabelle Amorim Ferreira Boza,&nbsp;Stéfani Laise da Silva,&nbsp;Nicolly Bittencourt Guedes,&nbsp;Giovana Carolina Bazzo,&nbsp;Hellen Karine Stulzer","doi":"10.1208/s12249-024-03012-4","DOIUrl":"10.1208/s12249-024-03012-4","url":null,"abstract":"<div><p>Developing orally administered pediatric formulations presents significant challenges due to the unique characteristics of pediatric patients. Terbinafine hydrochloride (TER), a powerful antifungal agent, is effective against various fungal infections, including <i>Tinea capitis</i>, which is common in children. However, its low aqueous solubility necessitates innovative pharmaceutical strategies to enhance its effectiveness. This study describes a rational approach to selecting suitable carriers, approved for use in children, to increase the apparent solubility of TER and to guide the development of amorphous solid dispersions containing this drug. Assessments of solubility parameters, equilibrium solubility measurements, and calculations of pediatric dose numbers guided formulation development using theoretical and experimental methodologies. Carriers like Plasdone S-360 ULTRA®, HPMCAS L, and Soluplus® demonstrated favorable solubility parameter values with TER, indicating potential for drug solubilization. The solubility of TER was strongly dependent on pH. In buffer pH 6.5 containing 10% (w/v) of Soluplus®, TER presented the highest solubility value. The solid-state characterization techniques employed to assess the precipitate formed after equilibrium solubility studies during preformulation demonstrated that there were no phase transitions and no significant interactions between the drug and the evaluated carriers. Furthermore, the results demonstrate that Soluplus® achieved the lowest dose number (0.23) for pediatric patients over 6 years old. So, it was selected for preparing the amorphous solid dispersion via spray drying, which significantly enhanced the apparent solubility of TER while maintaining prolonged supersaturation, offering a promising alternative for developing solid formulations of this drug, particularly for pediatric patients, as it aims to improve oral bioavailability.</p><h3>Graphical Abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":6925,"journal":{"name":"AAPS PharmSciTech","volume":"26 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142994426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Microfluidic Approach for Enhanced Paeoniflorin Transdermal Delivery: A Comparative Study on Different Chips and Mixing Dynamics 微流控方法增强芍药苷透皮给药:不同芯片和混合动力学的比较研究
IF 3.4 4区 医学
AAPS PharmSciTech Pub Date : 2025-01-16 DOI: 10.1208/s12249-024-03033-z
Qifei Gu, Wuqing Xiao, Yingyin Zhu, Wanling Zhong, Xue Sui, Yongchao Liu, Jie Zhang, Huichao Wu, Rui Zhou
{"title":"Microfluidic Approach for Enhanced Paeoniflorin Transdermal Delivery: A Comparative Study on Different Chips and Mixing Dynamics","authors":"Qifei Gu,&nbsp;Wuqing Xiao,&nbsp;Yingyin Zhu,&nbsp;Wanling Zhong,&nbsp;Xue Sui,&nbsp;Yongchao Liu,&nbsp;Jie Zhang,&nbsp;Huichao Wu,&nbsp;Rui Zhou","doi":"10.1208/s12249-024-03033-z","DOIUrl":"10.1208/s12249-024-03033-z","url":null,"abstract":"<div><p>Paeoniflorin is a natural pharmaceutical ingredient with a widely biological activity. However, as a hydrophilic drug, the problem of low transdermal rate limits its clinical application. To overcome this shortage, LUVs were used as biocompatible carriers of paeoniflorin in this study. We prepared paeoniflorin-loaded large unilamellar vesicles (LUVs) with W/O/W structure by microfluidics. We used four kinds of chips to prepare paeoniflorin LUVs and explored the effects of the chip structures on LUVs properties applying both experiments and numerical simulations. The difference of fluid mixing mechanisms was analyzed among four different channels, including straight and curved structures. Then we evaluated the differences in skin permeability among the three groups, paeoniflorin aqueous solution group, drug-loaded liposome group and blank liposome &amp; drug mixture group, using the abdominal skin of male mice. The results showed that the structure of the microfluidic channel was a key factor affecting the flow rate and mixing efficiency. The mixing efficiency further affected the liposome size. The mixing efficiency of curved channel was not better than that of a straight channel due to the low flow rate and long mixing time. By the results of transdermal experiments, LUVs could reduce the transdermal time and increase the total transdermal amount. LUVs effectively improved the transdermal absorption efficiency of paeoniflorin. In conclusion, paeoniflorin LUVs with highly efficient transdermal were successfully prepared by using microfluidics. We explored the underlying fluid dynamics that lead to variations in the preparation with different chip structures. The transdermal effect of the LUVs was verified.</p><h3>Graphical Abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":6925,"journal":{"name":"AAPS PharmSciTech","volume":"26 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1208/s12249-024-03033-z.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142994425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of CPAP Overlay Interfaces for Efficient Administration of Aerosol Surfactant Therapy to Preterm Infants 用于早产儿气溶胶表面活性剂有效给药的CPAP覆盖界面的开发
IF 3.4 4区 医学
AAPS PharmSciTech Pub Date : 2025-01-16 DOI: 10.1208/s12249-024-02987-4
Hasan Jubaer, Sarah Strickler, Dale Farkas, Caleb Dalton, Mohammad A. M. Momin, Kelley M. Dodson, Michael Hindle, Worth Longest
{"title":"Development of CPAP Overlay Interfaces for Efficient Administration of Aerosol Surfactant Therapy to Preterm Infants","authors":"Hasan Jubaer,&nbsp;Sarah Strickler,&nbsp;Dale Farkas,&nbsp;Caleb Dalton,&nbsp;Mohammad A. M. Momin,&nbsp;Kelley M. Dodson,&nbsp;Michael Hindle,&nbsp;Worth Longest","doi":"10.1208/s12249-024-02987-4","DOIUrl":"10.1208/s12249-024-02987-4","url":null,"abstract":"<div><p>The administration of surfactant aerosol therapy to preterm infants receiving continuous positive airway pressure (CPAP) respiratory support is highly challenging due to small flow passages, relatively high ventilation flow rates, rapid breathing and small inhalation volumes. To overcome these challenges, the objective of this study was to implement a validated computational fluid dynamics (CFD) model and develop an overlay nasal prong interface design for use with CPAP respiratory support that enables high efficiency powder aerosol delivery to the lungs of preterm infants when needed (i.e., on-demand) and can remain in place without increasing the work of breathing compared with a baseline CPAP interface. Realistic <i>in vitro</i> experiments were first conducted to generate baseline validation data, and then the CFD model, once validated, was used to explore key design parameters across a range of preterm infant nose-throat geometries and aerosol delivery conditions. The most important factors for efficient aerosol delivery were shown to be (i) maintaining the aerosol delivery flow rate below the tracheal flow rate (to minimize CPAP line loss) and (ii) concentrating the aerosol within the first portion of the inhalation waveform. An optimized design was shown to deliver approximately 37–60% of the nominal dose through the system and to the lungs with low intersubject variability (1050–2200 g infants) across two modes of device actuation (automated and manual) with room for further improvement. Ergonomic curvatures and streamlining of the prong geometries were also found to reduce work of breathing and flow resistance compared with a commercial alternative.</p><h3>Graphical Abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":6925,"journal":{"name":"AAPS PharmSciTech","volume":"26 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1208/s12249-024-02987-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142994379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Silica Nanoparticles: A Promising Vehicle for Anti-Cancer Drugs Delivery 二氧化硅纳米颗粒:一种有前途的抗癌药物递送载体
IF 3.4 4区 医学
AAPS PharmSciTech Pub Date : 2025-01-13 DOI: 10.1208/s12249-024-02982-9
T. Naga Aparna, Rohit Kumar, Shah Raj Ali, Dhaval J. Patel, Kazi Julekha, Touseef Begum, Jyoti Bala, Pawan Kumar
{"title":"Silica Nanoparticles: A Promising Vehicle for Anti-Cancer Drugs Delivery","authors":"T. Naga Aparna,&nbsp;Rohit Kumar,&nbsp;Shah Raj Ali,&nbsp;Dhaval J. Patel,&nbsp;Kazi Julekha,&nbsp;Touseef Begum,&nbsp;Jyoti Bala,&nbsp;Pawan Kumar","doi":"10.1208/s12249-024-02982-9","DOIUrl":"10.1208/s12249-024-02982-9","url":null,"abstract":"<div><p>The prevalence and death due to cancer have been rising over the past few decades, and eliminating tumour cells without sacrificing healthy cells remains a difficult task. Due to the low specificity and solubility of drug molecules, patients often require high dosages to achieve the desired therapeutic effects. Silica nanoparticles (SiNPs) can effectively deliver therapeutic agents to targeted sites in the body, addressing these challenges. Using SiNPs as vehicles for anti-cancer drug delivery has emerged as a promising strategy due to their unique structural properties, biocompatibility, and versatility. This review explores the various aspects of SiNPs in cancer therapy, highlighting their synthesis, functionalization, and application in delivering chemotherapeutic agents, photosensitizers, and nucleic acids. SiNPs offer advantages such as high drug loading capacity, controlled release, and targeted delivery, enhancing therapeutic efficacy and reducing systemic toxicity. Moreover, this review aims to provide an in-depth understanding of the current state and prospects of SiNPs in revolutionizing cancer treatment and improving patient outcomes.</p><h3>Graphical Abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":6925,"journal":{"name":"AAPS PharmSciTech","volume":"26 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142976418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: From Bench to Bedside: ROS-Responsive Nanocarriers in Cancer Therapy 更正:从实验室到床边:肿瘤治疗中的ros反应性纳米载体
IF 3.4 4区 医学
AAPS PharmSciTech Pub Date : 2025-01-13 DOI: 10.1208/s12249-024-03036-w
Abhishek Chauhan, Raj Kamal, Rohit Bhatia, Thakur Gurjeet Singh, Ankit Awasthi
{"title":"Correction: From Bench to Bedside: ROS-Responsive Nanocarriers in Cancer Therapy","authors":"Abhishek Chauhan,&nbsp;Raj Kamal,&nbsp;Rohit Bhatia,&nbsp;Thakur Gurjeet Singh,&nbsp;Ankit Awasthi","doi":"10.1208/s12249-024-03036-w","DOIUrl":"10.1208/s12249-024-03036-w","url":null,"abstract":"","PeriodicalId":6925,"journal":{"name":"AAPS PharmSciTech","volume":"26 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142976417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Understanding Microemulsions and Nanoemulsions in (Trans)Dermal Delivery 了解微乳液和纳米乳液在(经)皮递送中的作用
IF 3.4 4区 医学
AAPS PharmSciTech Pub Date : 2025-01-10 DOI: 10.1208/s12249-024-02997-2
Jasmine Musakhanian, David W. Osborne
{"title":"Understanding Microemulsions and Nanoemulsions in (Trans)Dermal Delivery","authors":"Jasmine Musakhanian,&nbsp;David W. Osborne","doi":"10.1208/s12249-024-02997-2","DOIUrl":"10.1208/s12249-024-02997-2","url":null,"abstract":"<div><p>Continuously explored in pharmaceuticals, microemulsions and nanoemulsions offer drug delivery opportunities that are too significant to ignore, namely safe delivery of clinically relevant drug doses across biological membranes. Their effectiveness as drug vehicles in mucosal and (trans)dermal delivery is evident from the volume of published literature. Commonly, their ability to enhance skin permeation is attributed to dispersion size, a characteristic closely related to solubilization capacity. However, the literature falls short on distinctions between microemulsions and nanoemulsions for definitions, behavior, or specific differences in their mechanisms of action in (trans)dermal delivery. The focus is typically on surfactant/cosurfactant ratio and droplet size but the role of mesostructures or the effect of cosolvent (C<sub>sol</sub>), oil (O) or water (W) on permeation profile remain poorly explained. Towards a deeper understanding of these vehicles in (trans)dermal drug delivery, this review begins with their conceptual and practical distinctions before delving into the published works for less obvious but potentially important underlying mechanisms; notably composition and the competitive positioning of system constituents in the resulting microstructures and subsequent effect(s) these may have on skin structures and drug permeability. For practical purposes, this review focuses on formulation systems based on ternary diagrams with commonly accepted non-ionic surfactants, cosurfactants, cosolvents, and oils used in pharmaceutical applications.</p><h3>Graphical Abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":6925,"journal":{"name":"AAPS PharmSciTech","volume":"26 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1208/s12249-024-02997-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142941203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advancements in Transdermal Drug Delivery Systems: Harnessing the Potential of Macromolecular Assisted Permeation Enhancement and Novel Techniques 经皮给药系统的进展:利用大分子辅助渗透增强的潜力和新技术
IF 3.4 4区 医学
AAPS PharmSciTech Pub Date : 2025-01-09 DOI: 10.1208/s12249-024-03029-9
Pratikeswar Panda, Tejaswini Mohanty, Rajaram Mohapatra
{"title":"Advancements in Transdermal Drug Delivery Systems: Harnessing the Potential of Macromolecular Assisted Permeation Enhancement and Novel Techniques","authors":"Pratikeswar Panda,&nbsp;Tejaswini Mohanty,&nbsp;Rajaram Mohapatra","doi":"10.1208/s12249-024-03029-9","DOIUrl":"10.1208/s12249-024-03029-9","url":null,"abstract":"<div><p>Transdermal drug delivery (TDD) represents a transformative paradigm in drug administration, offering advantages such as controlled drug release, enhanced patient adherence, and circumvention of hepatic first-pass metabolism. Despite these benefits, the inherent barrier function of the skin, primarily attributed to the stratum corneum, remains a significant impediment to the efficient permeation of therapeutic agents. Recent advancements have focused on macromolecular-assisted permeation enhancers, including carbohydrates, lipids, amino acids, nucleic acids, and cell-penetrating peptides, which modulate skin permeability by transiently altering its structural integrity. Concurrently, innovative methodologies such as iontophoresis, electroporation, microneedles, ultrasound, and sonophoresis have emerged as potent tools to enhance drug transport by creating transient microchannels or altering the skin's microenvironment. Among the novel approaches, the development of nanocarriers such as Liposome, niosomes, and transethosomes etc. has garnered substantial attention. These elastic vesicular systems, comprising lipids and edge activators, exhibit superior skin penetration owing to their deformability and enhanced payload delivery capabilities. Furthermore, the integration of nanocarriers with physical enhancement techniques demonstrates a synergistic potential, effectively addressing the limitations of conventional TDD systems. This comprehensive convergence of macromolecular-assisted enhancers, advanced physical techniques, and next-generation nanocarriers underscores the evolution of TDD, paving the way for optimized therapeutic outcomes.</p><h3>Graphical Abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":6925,"journal":{"name":"AAPS PharmSciTech","volume":"26 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142939152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Concerns Regarding the Use of Kirchhoff’s Laws in Pharmacokinetics 关于在药代动力学中使用基尔霍夫定律的关注
IF 3.4 4区 医学
AAPS PharmSciTech Pub Date : 2025-01-09 DOI: 10.1208/s12249-024-03019-x
Svein Øie
{"title":"Concerns Regarding the Use of Kirchhoff’s Laws in Pharmacokinetics","authors":"Svein Øie","doi":"10.1208/s12249-024-03019-x","DOIUrl":"10.1208/s12249-024-03019-x","url":null,"abstract":"<div><p>Over the last two years the idea that the principles presented in Kirchhoff’s circuit and voltage laws also pertain to pharmacokinetics (1–3). It is claimed that these principles make the elimination in the liver and kidney more straight forward to model and provide a rationale for understanding why sometimes during bioavailability studies one arrives at bioavailability values greater than 100%. In this paper it will be shown that these claims are based on incorrect translations of the Kirchhoff’s Laws to pharmacokinetics.</p></div>","PeriodicalId":6925,"journal":{"name":"AAPS PharmSciTech","volume":"26 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1208/s12249-024-03019-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142939151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信